Affiliation:
1. Peoples Friendship University of Russia; Medical Institute, Moscow, Russia
Abstract
The term «acute respiratory viral infections» refers to a group of diseases
whose etiological agents are respiratory viruses, mainly affecting the epithelium of the
upper respiratory tract. The article presents the results of studying the effectiveness of
the drug Nobazit® in 32 patients with body temperature > 37.5 °C having at least one catarrhal symptom (cough, rhinitis, or sore throat) and one symptom of intoxication
(chills, sweating, malaise, weakness, or headache) who consulted a doctor within
the first 48 hours from the onset of symptoms of an acute respiratory viral infection.
The use of the drug Nobazit® (enisamium iodide) allowed to reduce the severity of
clinical manifestations, eliminate lymphopenia, normalize factors of innate and adaptive
immunity, and restore the receptor landscape of peripheral blood lymphocytes. The
registered clinical and immunological efficacy of the drug Nobazit® allows recommending
its inclusion in the complex therapy of acute respiratory infections.
Publisher
PANORAMA Publishing House
Reference21 articles.
1. Dolgushin I. I. Immunoprophylaxis of infectious diseases. Educational and methodological guide.I. I. Dolgushin, O. A. Gizinger, S. V. Luchinina. Chelyabinsk. 2014; 112.
2. Zaplatnikov A. L. Immunoprophylaxis and immunotherapy of acute respiratory infections in children. Attending physician. 2006; 9: 50–56.
3. Pshenichnaya N. Yu., et al. Overview of current and prospective directions of antiviral therapy for infl uenza and acute respiratory viral infections in Russia. Therapeutic archive. 2019; 91 (11): 105–109. https://doi.org/10.26442/00403660.2020.03.000572.
4. Vikulov G. Kh. Viral, bacterial respiratory infections, immunity and antibiotic therapy: what do they have in common? The view and recommendations of a clinical immunologist and infectious disease specialist. ConsiliumMedicum. 2015; 17 (11): 35–41.
5. Paevskaya O. A., Zuevskaya S. N., Nikiforov V. V., Belaya O. F., Kolaeva N. V., Nemilostiva E. A., Kanshina N. N., Turkadze K. A. Possibilities of etiotropic therapy in reducing the risks of severe or complicated course of SARS and infl uenza. RMJ. 30.04.2019; 1 (II): 77–80. Available at: https:// www.rmj.ru/articles/infektsiya/Vozmoghnosti_etiotropnoy_terapii_v_snighenii_riskov_razvitiya_tyaghelogo_ili_osloghnennogo_techeniya_ORVI_i_grippa/#ixzz6RIbNoXxe.